Lantheus Holdings Inc. is adding to its portfolio yet again, acquiring a clinical-stage radiopharmaceutical company in a deal worth up to about $1 billion. Lantheus Holdings Inc. is adding to its ...
Lantheus (LNTH) announced the appointment of Phuong Khanh Morrow, M.D. to Lantheus’ Board of Directors, effective February 1, 2025. As an ...
Well before market open that morning, Lantheus announced that it has signed a definitive agreement to acquire clinical-stage peer Evergreen Theragnostics. For its new asset, Lantheus will make an ...
Matthew Taylor, an analyst from Jefferies, reiterated the Buy rating on Lantheus (LNTH – Research Report). The associated price target was lowered to $135.00. Discover outperforming stocks and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback